Feedback Valuation
Is GZM0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of GZM0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate GZM0's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate GZM0's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GZM0?
Key metric: As GZM0 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is GZM0's PS Ratio? | |
|---|---|
| PS Ratio | 2.3x |
| Sales | UK£1.18m |
| Market Cap | UK£2.73m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does GZM0's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.9x | ||
M3V MeVis Medical Solutions | 2.6x | n/a | €45.1m |
AJ91 DocCheck | 0.8x | n/a | €42.1m |
TLIK Arzneiwerk VIDA | 0.08x | n/a | €4.5m |
EIF MedNation | 0.1x | n/a | €5.0m |
GZM0 Feedback | 2.3x | 44.9% | €2.7m |
Price-To-Sales vs Peers: GZM0 is expensive based on its Price-To-Sales Ratio (2.3x) compared to the peer average (0.9x).
Price to Sales Ratio vs Industry
How does GZM0's PS Ratio compare vs other companies in the European Healthcare Services Industry?
| 5 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: GZM0 is expensive based on its Price-To-Sales Ratio (2.3x) compared to the European Healthcare Services industry average (2.2x).
Price to Sales Ratio vs Fair Ratio
What is GZM0's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.3x |
| Fair PS Ratio | 6.4x |
Price-To-Sales vs Fair Ratio: GZM0 is good value based on its Price-To-Sales Ratio (2.3x) compared to the estimated Fair Price-To-Sales Ratio (6.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Shandong Weigao Group Medical Polymer
HK$20.1b
Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.
UK2
HK$0.52
7D
-1.0%
1Y
-38.8%
LNA Santé
€244.4m
Engages in the management and operation of health establishments.
2N3
€23.25
7D
-6.1%
1Y
16.0%
OrbusNeich Medical Group Holdings
HK$3.4b
An investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States.
Q8T
HK$0.51
7D
12.2%
1Y
-43.3%